Research programme: immunotherapeutics - ImmunOs Therapeutics

Drug Profile

Research programme: immunotherapeutics - ImmunOs Therapeutics

Alternative Names: ios Ab1; ios H1; ios H2; ios H3; ios H4; ios H5

Latest Information Update: 08 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunOs Therapeutics
  • Class Antineoplastics; Immunoproteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 08 Sep 2016 Early research in Cancer in Switzerland (unspecified route) before September 2016 (ImmunOs Therapeutics Pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top